G蛋白偶联受体(GPCRs)广泛存在于体内,参与多种生理过程,从而成为药物开发的重要靶点。大约30%的食品和药物管理局(FDA)批准的药物靶向GPCRs。迄今为止,一种疾病,一个目标,一种分子策略不再满足药物开发的需求。同时,小分子药物占FDA批准药物的60%。中医以其独特的理论体系和治疗方法引起了广泛的关注。TCM涉及多个组件,目标和途径。以GPCRs和TCM为中心,本文从中医证候的角度探讨了中医与GPCRs的异同,中药多组分和多靶点方法的一致性以及GPCRs和中药在新药开发中的潜力。一种新颖的策略,“同时筛选药物和目标”,提出并应用于GPCRs的研究。我们将GPCRs与TCM相结合,以促进TCM的现代化,为中药的合理应用提供有价值的见解,促进新药的研发。本研究为中药现代化提供了理论支持,并为开发安全有效的药物提供了新的思路。
G protein-coupled receptors (GPCRs) widely exist in vivo and participate in many physiological processes, thus emerging as important targets for drug development. Approximately 30% of the Food and Drug Administration (FDA)-approved drugs target GPCRs. To date, the \'one disease, one target, one molecule\' strategy no longer meets the demands of drug development. Meanwhile, small-molecule drugs account for 60% of FDA-approved drugs. Traditional Chinese medicine (TCM) has garnered widespread attention for its unique theoretical system and treatment methods. TCM involves multiple components, targets and pathways. Centered on GPCRs and TCM, this paper discusses the similarities and differences between TCM and GPCRs from the perspectives of syndrome of TCM, the consistency of TCM\'s multi-component and multi-target approaches and the potential of GPCRs and TCM in the development of novel drugs. A novel strategy, \'simultaneous screening of drugs and targets\', was proposed and applied to the study of GPCRs. We combine GPCRs with TCM to facilitate the modernisation of TCM, provide valuable insights into the rational application of TCM and facilitate the research and development of novel drugs. This study offers theoretical support for the modernisation of TCM and introduces novel ideas for development of safe and effective drugs.